The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Serentil     10-[2-(1-methyl-2- piperidyl)ethyl]-2...

Synonyms: Calodal, Lidanar, Lidanil, Mesoridazina, mesoridazine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Serentil


Psychiatry related information on Serentil


High impact information on Serentil


Biological context of Serentil

  • Mesoridazine blocked HERG currents in a concentration-dependent manner (IC50 550 nM at 0 mV); block increased significantly over the voltage range where HERG activates and saturated at voltages eliciting maximal HERG channel activation [10].
  • A significant decrease in the mean AUC infinity 0 or AUCt0 was observed for mesoridazine after the administration of the divided dose.(ABSTRACT TRUNCATED AT 250 WORDS)[12]
  • Studies on thioridazine and mesoridazine metabolism. I. Protein binding [13].

Anatomical context of Serentil


Associations of Serentil with other chemical compounds


Gene context of Serentil


Analytical, diagnostic and therapeutic context of Serentil


  1. Mesoridazine use and priapism. Starck, L.C., Talley, B.J., Brannan, S.K. The American journal of psychiatry. (1994) [Pubmed]
  2. Complete heart block associated with mesoridazine and lithium combination. Salama, A.A. The Journal of clinical psychiatry. (1987) [Pubmed]
  3. Schizophrenia, antipsychotic drugs, and cardiovascular disease. Glassman, A.H. The Journal of clinical psychiatry. (2005) [Pubmed]
  4. Cardiotoxic manifestations of mesoridazine overdose. Marrs-Simon, P.A., Zell-Kanter, M., Kendzierski, D.L., Leikin, J.B. Annals of emergency medicine. (1988) [Pubmed]
  5. Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Smith, R.C., Baumgartner, R., Ravichandran, G.K., Shvartsburd, A., Schoolar, J.C., Allen, P., Johnson, R. Psychiatry research. (1984) [Pubmed]
  6. Mesoridazine (Serentil) in personality disorders--a controlled trial in adolescent patients. Barnes, R.J. Diseases of the nervous system. (1977) [Pubmed]
  7. Mesoridazine in Huntington's disease (chorea): effect on weight, dyskinesia, and mental function. Drymiotis, A., Korenyi, C., Whittier, J.R. Current therapeutic research, clinical and experimental. (1976) [Pubmed]
  8. A unitary mechanism of calcium antagonist drug action. Murphy, K.M., Gould, R.J., Largent, B.L., Snyder, S.H. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  9. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. Shvartsburd, A., Sajadi, C., Morton, V., Mirabi, M., Gordon, J., Smith, R.C. Journal of clinical psychopharmacology. (1984) [Pubmed]
  10. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. Su, Z., Martin, R., Cox, B.F., Gintant, G. J. Mol. Cell. Cardiol. (2004) [Pubmed]
  11. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Roth, B.L., Tandra, S., Burgess, L.H., Sibley, D.R., Meltzer, H.Y. Psychopharmacology (Berl.) (1995) [Pubmed]
  12. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. Chakraborty, B.S., Midha, K.K., McKay, G., Hawes, E.M., Hubbard, J.W., Korchinski, E.D., Choc, M.G., Robinson, W.T. Journal of pharmaceutical sciences. (1989) [Pubmed]
  13. Studies on thioridazine and mesoridazine metabolism. I. Protein binding. Forrest, I.S., Green, D.E., Blum, A., Serra, M.T., Loeffler, K.O. Communications in psychopharmacology. (1979) [Pubmed]
  14. Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients. Shvartsburd, A., Nwokeafor, V., Smith, R.C. Psychopharmacology (Berl.) (1984) [Pubmed]
  15. Effect of thioridazine on gap junction intercellular communication in connexin 43-expressing cells. Matesic, D.F., Abifadel, D.N., Garcia, E.L., Jann, M.W. Cell Biol. Toxicol. (2006) [Pubmed]
  16. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Cohen, B.M., Lipinski, J.F., Waternaux, C. Psychopharmacology (Berl.) (1989) [Pubmed]
  17. Mesoridazine and human sleep. Adam, K., Allen, S., Carruthers-Jones, I., Oswald, I., Spence, M. British journal of clinical pharmacology. (1976) [Pubmed]
  18. Development of a radioimmunoassay procedure for mesoridazine and its comparison with a high-performance liquid chromatographic method. Chakraborty, B.S., Hawes, E.M., Midha, K.K. Therapeutic drug monitoring. (1987) [Pubmed]
  19. Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. White, K., Busk, J., Eaton, E., Gomez, G., Razani, J., Sloane, R.B. International pharmacopsychiatry. (1981) [Pubmed]
  20. Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Choi, S., Haggart, D., Toll, L., Cuny, G.D. Bioorg. Med. Chem. Lett. (2004) [Pubmed]
  21. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Llerena, A., Berecz, R., de la Rubia, A., Norberto, M.J., Benítez, J. Therapeutic drug monitoring. (2000) [Pubmed]
  22. Synthesis and properties of haptens for the development of radioimmunoassays for thioridazine, mesoridazine, and sulforidazine. Chakraborty, B.S., Sardessai, M.S., Jaworski, T.J., Midha, K.K., Hawes, E.M. Pharm. Res. (1987) [Pubmed]
  23. Degradation and configurational changes of thioridazine 2-sulfoxide. de Gaitani, C.M., Martinez, A.S., Bonato, P.S. Journal of pharmaceutical and biomedical analysis. (2004) [Pubmed]
WikiGenes - Universities